Psoriatic Arthritis News and Research

RSS
Like rheumatoid arthritis (RA), psoriatic arthritis is a chronic inflammatory disease of the joints and connective tissue. The disease causes joint pain and swelling that can lead to crippling along with inflamed and irritated scaly red patches of skin throughout the body. It is a progressive and debilitating disease and because there are no treatments specifically approved for psoriatic arthritis, doctors often use therapies approved for RA, including nonsteroidal anti-inflammatory drugs (NSAIDs) and disease modifying anti-rheumatic drugs (DMARDs). However, no DMARDs are currently approved for use in psoriatic arthritis. There are approximately 300,000 patients with psoriatic arthritis in the United States and the disease affects both men and women most commonly between the ages 30 and 50. Psoriatic arthritis patients are generally treated by rheumatologists and dermatologists.
Review sheds new light on link between smoking habits and psoriasis

Review sheds new light on link between smoking habits and psoriasis

People diagnosed with psoriatic arthritis often left with little or no support for emotional problems

People diagnosed with psoriatic arthritis often left with little or no support for emotional problems

Inflectra (infliximab-dyyb) approved for multiple indications

Inflectra (infliximab-dyyb) approved for multiple indications

LEO Pharma announces scientific approval of Enstilar for treatment of people living with psoriasis in EU

LEO Pharma announces scientific approval of Enstilar for treatment of people living with psoriasis in EU

Patients with moderate-to-severe plaque psoriasis achieve significant improvement with ixekizumab

Patients with moderate-to-severe plaque psoriasis achieve significant improvement with ixekizumab

BENEPALI granted marketing authorization in the EU for treatment of chronic inflammatory diseases

BENEPALI granted marketing authorization in the EU for treatment of chronic inflammatory diseases

Novartis announces FDA approval of Cosentyx for treatment of adult patients with AS and PsA

Novartis announces FDA approval of Cosentyx for treatment of adult patients with AS and PsA

NEJM publishes results of Cosentyx Phase III studies in ankylosing spondylitis

NEJM publishes results of Cosentyx Phase III studies in ankylosing spondylitis

Complix signs agreement with Selexis to advance production of autoimmune drug candidate CMX-02

Complix signs agreement with Selexis to advance production of autoimmune drug candidate CMX-02

Novartis announces EC approval of Cosentyx for treatment of ankylosing spondylitis, psoriatic arthritis

Novartis announces EC approval of Cosentyx for treatment of ankylosing spondylitis, psoriatic arthritis

No progression in joint damage in 84% of psoriatic arthritis patients

No progression in joint damage in 84% of psoriatic arthritis patients

CHMP recommends approval of Cosentyx in Europe to treat patients with AS and PsA, says Novartis

CHMP recommends approval of Cosentyx in Europe to treat patients with AS and PsA, says Novartis

LEO Pharma's Enstilar gets FDA approval for topical treatment of plaque psoriasis

LEO Pharma's Enstilar gets FDA approval for topical treatment of plaque psoriasis

Phase II psoriasis study shows efficacy of Boehringer Ingelheim's BI 655066 over ustekinumab

Phase II psoriasis study shows efficacy of Boehringer Ingelheim's BI 655066 over ustekinumab

Hospira announces TGA approval of Inflectra (infliximab) for treatment of eight inflammatory conditions

Hospira announces TGA approval of Inflectra (infliximab) for treatment of eight inflammatory conditions

Results of IPC survey identifying 21 psoriasis research priorities published in British Journal of Dermatology

Results of IPC survey identifying 21 psoriasis research priorities published in British Journal of Dermatology

National Psoriasis Foundation introduces patient-centered research network

National Psoriasis Foundation introduces patient-centered research network

MSD announces EC approval of SIMPONI (golimumab) for treatment of adult patients with nr-axial SpA

MSD announces EC approval of SIMPONI (golimumab) for treatment of adult patients with nr-axial SpA

Switching from Remicade to Inflectra benefits patients with rheumatic diseases

Switching from Remicade to Inflectra benefits patients with rheumatic diseases

LEO Pharma reports encouraging data from PSO-FAST clinical trial of Enstilar for psoriasis treatment

LEO Pharma reports encouraging data from PSO-FAST clinical trial of Enstilar for psoriasis treatment